Welcome to VivoMedica Welcome to VivoMedica

Welcome to VivoMedica

VivoMedica plc is a British company that delivers high value technology solutions to the global Pharmaceutical Industry. These specialist Pharma-Ware solutions are designed to improve the cost, efficiency and effectiveness of the complex processes involved in the discovery and development of drugs, and in their effective use in treatment pathways. Our company identifies, licenses and develops technologies that support these crucial process developments, and integrates them into products and service offerings that address the challenging needs of the global healthcare market.

VivoMedica’s initial portfolio of products is developed from a suite of patented healthcare technologies licensed from QinetiQ, and provides innovative solutions in the field of cardiotoxicity testing in drug development (DrugPrint®).

 

Latest News

Introducing... the CARDIOTOX industry consortium
Launching 17/09/2009 at the SPS meeting in Strasbourg, France, the Consortium will validate a new, distinct cardiotoxicity and proarrhythmia screening tool using CDI's iCells and VivoMedica's DrugPrint technology.
»  Read More
DrugPrint® could cut the cost of preclinical research
DrugPrint®, a novel technology for lead compound cardiotoxicity profiling could provide a way to reduce the number of drug casualties in the early stages of drug discovery.
 »  Read More

Company News

VivoMedica completes delisting from AIM.
Today VivoMedica completed the process of cancelling trading of the company's ordinary shares on the London AIM stock market.
 »  Read More